Zacks Investment Research upgraded shares of ProQR Therapeutics (NASDAQ:PRQR) from a sell rating to a hold rating in a report published on Wednesday.
According to Zacks, “ProQR Therapeutics B.V. is a biotech company. It is engaged in the discovery and development of RNA-based therapeutics for the treatment of severe genetic disorders, with an initial focus on Cystic Fibrosis (CF). The Company’s lead product candidate includes QR-010, a RNA-based oligonucleotide for the treatment of cystic fibrosis. ProQR Therapeutics B.V. is headquartered in Leiden, the Netherlands. “
Several other research analysts have also recently issued reports on the stock. Evercore ISI started coverage on shares of ProQR Therapeutics in a report on Tuesday, September 18th. They issued an outperform rating and a $35.00 target price for the company. ValuEngine cut shares of ProQR Therapeutics from a strong-buy rating to a buy rating in a report on Thursday, August 30th. HC Wainwright set a $20.00 target price on shares of ProQR Therapeutics and gave the company a buy rating in a report on Thursday, August 9th. BidaskClub upgraded shares of ProQR Therapeutics from a buy rating to a strong-buy rating in a report on Wednesday, October 24th. Finally, Chardan Capital restated a buy rating and issued a $9.00 target price on shares of ProQR Therapeutics in a report on Monday, August 13th. One analyst has rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. ProQR Therapeutics has a consensus rating of Buy and a consensus price target of $18.00.
ProQR Therapeutics (NASDAQ:PRQR) last issued its earnings results on Wednesday, November 7th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.10. On average, equities research analysts expect that ProQR Therapeutics will post -1.38 earnings per share for the current fiscal year.
Several institutional investors have recently modified their holdings of PRQR. JPMorgan Chase & Co. boosted its holdings in shares of ProQR Therapeutics by 519.0% in the 1st quarter. JPMorgan Chase & Co. now owns 33,425 shares of the biopharmaceutical company’s stock valued at $103,000 after buying an additional 28,025 shares in the last quarter. Ardsley Advisory Partners acquired a new position in shares of ProQR Therapeutics in the 2nd quarter valued at $365,000. Essex Investment Management Co. LLC acquired a new position in shares of ProQR Therapeutics in the 2nd quarter valued at $604,000. Franklin Street Advisors Inc. NC boosted its holdings in shares of ProQR Therapeutics by 50.0% in the 2nd quarter. Franklin Street Advisors Inc. NC now owns 90,000 shares of the biopharmaceutical company’s stock valued at $657,000 after buying an additional 30,000 shares in the last quarter. Finally, Millennium Management LLC acquired a new position in shares of ProQR Therapeutics in the 2nd quarter valued at $1,426,000. Institutional investors and hedge funds own 28.55% of the company’s stock.
About ProQR Therapeutics
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. Its lead product candidates include eluforsen, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide that is designed to treat Leber's congenital amaurosis; QR-313, a dermatology candidate for the treatment of epidermolysis bullosa; and QR-421a and QR-411 to treat type 2A Usher syndrome.
See Also: How Do You Make Money With Penny Stocks?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.